141 related articles for article (PubMed ID: 31878146)
1. Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM).
Capron M; Béghin L; Leclercq C; Labreuche J; Dendooven A; Standaert A; Delbeke M; Porcherie A; Nachury M; Boruchowicz A; Dupas JL; Fumery M; Paupard T; Catteau S; Deplanque D; Colombel JF; Desreumaux P
J Clin Med; 2019 Dec; 9(1):. PubMed ID: 31878146
[TBL] [Abstract][Full Text] [Related]
2. Contribution of the Gut Microbiota in P28GST-Mediated Anti-Inflammatory Effects: Experimental and Clinical Insights.
Foligné B; Plé C; Titécat M; Dendooven A; Pagny A; Daniel C; Singer E; Pottier M; Bertin B; Neut C; Deplanque D; Dubuquoy L; Desreumaux P; Capron M; Standaert A
Cells; 2019 Jun; 8(6):. PubMed ID: 31212833
[TBL] [Abstract][Full Text] [Related]
3. Treatment with P28GST, a schistosome-derived enzyme, after acute colitis induction in mice: Decrease of intestinal inflammation associated with a down regulation of Th1/Th17 responses.
Sarazin A; Dendooven A; Delbeke M; Gatault S; Pagny A; Standaert A; Rousseaux C; Desreumaux P; Dubuquoy L; Capron M
PLoS One; 2018; 13(12):e0209681. PubMed ID: 30592734
[TBL] [Abstract][Full Text] [Related]
4. Preparation and investigation of P28GST-loaded PLGA microparticles for immunomodulation of experimental colitis.
Thi THH; Priemel PA; Karrout Y; Driss V; Delbeke M; Dendooven A; Flament MP; Capron M; Siepmann J
Int J Pharm; 2017 Nov; 533(1):26-33. PubMed ID: 28923765
[TBL] [Abstract][Full Text] [Related]
5. Trichuris suis therapy in Crohn's disease.
Summers RW; Elliott DE; Urban JF; Thompson R; Weinstock JV
Gut; 2005 Jan; 54(1):87-90. PubMed ID: 15591509
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.
Forbes GM; Sturm MJ; Leong RW; Sparrow MP; Segarajasingam D; Cummins AG; Phillips M; Herrmann RP
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):64-71. PubMed ID: 23872668
[TBL] [Abstract][Full Text] [Related]
7. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
[TBL] [Abstract][Full Text] [Related]
8. Low dose naltrexone for induction of remission in Crohn's disease.
Segal D; Macdonald JK; Chande N
Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
[TBL] [Abstract][Full Text] [Related]
9. Serum calprotectin as a biomarker for Crohn's disease.
Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
[TBL] [Abstract][Full Text] [Related]
10. Nicotine enemas for active Crohn's colitis: an open pilot study.
Ingram JR; Rhodes J; Evans BK; Thomas GA
Gastroenterol Res Pract; 2008; 2008():237185. PubMed ID: 18795117
[TBL] [Abstract][Full Text] [Related]
11. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
[TBL] [Abstract][Full Text] [Related]
12. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
13. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
Sobrado CW; Cançado RD; Sobrado LF; Frugis MO; Sobrado MF
Arq Gastroenterol; 2015 Dec; 52(4):255-9. PubMed ID: 26840464
[TBL] [Abstract][Full Text] [Related]
14. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.
Duijvestein M; Vos AC; Roelofs H; Wildenberg ME; Wendrich BB; Verspaget HW; Kooy-Winkelaar EM; Koning F; Zwaginga JJ; Fidder HH; Verhaar AP; Fibbe WE; van den Brink GR; Hommes DW
Gut; 2010 Dec; 59(12):1662-9. PubMed ID: 20921206
[TBL] [Abstract][Full Text] [Related]
15. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.
Sands BE; Winston BD; Salzberg B; Safdi M; Barish C; Wruble L; Wilkins R; Shapiro M; Schwertschlag US;
Aliment Pharmacol Ther; 2002 Mar; 16(3):399-406. PubMed ID: 11876692
[TBL] [Abstract][Full Text] [Related]
16. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.
Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA
Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic importance of faecal markers in long-term monitoring of anti-TNF-α therapy in primary responders with Crohn's disease.
Łykowska-Szuber L; Klimczak K; Eder P; Krela-Kaźmierczak I; Stawczyk-Eder K; Michalak M; Studniarek A; Kościński T; Szymczak A; Linke K
Prz Gastroenterol; 2016; 11(4):232-238. PubMed ID: 28053677
[TBL] [Abstract][Full Text] [Related]
18. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
[TBL] [Abstract][Full Text] [Related]
19. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive review and update on Crohn's disease.
Gajendran M; Loganathan P; Catinella AP; Hashash JG
Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
